The tumor lysate particle only cancer vaccine was tested in 187 patients in the phase 2 clinical trial. Nearly 95% of patients given only the vaccine were alive three years after starting treatment, and 64% were still disease-free.
Among stage 3 melanoma patients, 60% in the vaccine-only group were disease-free after three years, compared with 39% in the placebo group. Stage 4 melanoma patients had even higher disease-free survival at 68%.
The most common side effects were redness or pain at the injection site, and fever and fatigue after injection.
The phase 3 clinical trial is set to begin this year, Riley Polk, president of Orbis Health Solutions, told ABC affiliate WLOS. It will include 500 people and span three years.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
